6-K
BELITE BIO, INC (BLTE)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15b-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2025
Commission File Number: 001-41359
Belite Bio, Inc
(Exact name of registrant as specified in its charter)
Not Applicable
(Translation of Registrant´s name into English)
12750 High Bluff Drive Suite 475,
San Diego, CA 92130
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
On August 11, 2025, Belite Bio, Inc issued a press release entitled “Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update.” A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
This Report on Form 6-K shall be deemed to be incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933 and shall be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Belite Bio, Inc | |
|---|---|
| By: | /s/ Yu-Hsin Lin |
| Name: | Yu-Hsin Lin |
| Title: | Chief Executive Officer and Chairman |
Date: August 11, 2025
Exhibit 99.1
Belite Bio Reports Second Quarter 2025 Financial Results and Providesa Corporate Update
| · | Tinlarebant granted Breakthrough Therapy Designation for Stargardt disease (STGD1) by the U.S. Food and Drug Administration (FDA) |
|---|---|
| · | DRAGON trial completion expected by Q4 2025 (including a three-month follow-up period) |
| --- | --- |
| · | Enrollment completedwith 529 subjects in the pivotal phase 3 PHOENIX trial in geographic atrophy (GA) |
| --- | --- |
| · | Raised approximately $15 million in gross proceeds in a registered direct offering on August 8, 2025 |
| --- | --- |
| · | Conference call and webcast on Monday, August 11, 2025, at 4:30 p.m. ET |
| --- | --- |
SAN DIEGO, August 11, 2025- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the second quarter ended June 30, 2025, and provided a general business update.
“This quarter, we remained on track with the strategic objectives we outlined at the start of the year, including the completion of enrollment in our pivotal Phase 3 PHOENIX trial — an important milestone in our development efforts for people living with geographic atrophy,” said Dr. Tom Lin, Chairman and CEO of Belite Bio. “We also received Breakthrough Therapy Designation for Tinlarebant for the treatment of Stargardt disease from the FDA, underscoring its potential as the first-ever treatment for this patient population and acknowledging the significant unmet need for people living with this debilitating disease. With the DRAGON trial on track to complete by the end of this year, we remain focused on advancing Tinlarebant toward key clinical and regulatory milestones.”
Second Quarter 2025 Business Highlights and Upcoming Milestones:
Clinical Highlights
Tinlarebant (LBS-008) is an oral, potent, once-daily, retinol binding protein 4 (RBP4) antagonist that decreases RBP4 levels in the blood and reduces vitamin A (retinol) delivery to the eye without disrupting systemic retinol delivery to other tissues. Vitamin A is critical for normal vision but can accumulate as toxic byproducts in individuals affected with STGD1 and GA, the advanced form of dry age-related macular degeneration (AMD), leading to retinal cell death and loss of vision.
| · | Stargardt disease (STGD1): Accumulation of cytotoxic vitamin A byproducts (bisretinoids) compounds has been implicated<br> in the onset and progression of STGD1, for which there is no approved treatment. Tinlarebant<br> has been granted Breakthrough Therapy, Fast Track and Rare Pediatric Disease Designations<br> in the U.S.; Orphan Drug Designation in the U.S., Europe, and Japan; and Sakigake (Pioneer<br> Drug) Designation in Japan for the treatment of STGD1. |
|---|---|
| · | DRAGON Trial: Ongoing,<br> 24-month, randomized (2:1, active: placebo), double-masked, placebo-controlled, global, multi-center,<br> pivotal Phase 3 trial in adolescent STGD1 patients |
| --- | --- |
| · | Primary efficacy endpoint<br> is the growth rate of atrophic lesions; safety and tolerability will also be assessed. |
| --- | --- |
| · | Following a pre-specified<br> interim analysis, an independent Data Safety Monitoring Board (DSMB) recommended trial continuation<br> without modifications, maintaining a sample size of 104 subjects, and recommended submission<br> of the data for regulatory review for drug approval. |
| --- | --- |
| · | The Breakthrough Therapy<br> Designation was supported by the interim data of the DRAGON trial. The designation is based<br> on preliminary clinical evidence indicating that a drug may demonstrate substantial improvement<br> over existing therapies on one or more clinically significant endpoints. Currently STGD1<br> has no approved treatment. |
| --- | --- |
| · | Belite expects trial completion<br> by Q4 2025 (including a three-month follow-up period) and plans to submit DRAGON trial data<br> for drug approval. |
| --- | --- |
| · | DRAGON II Trial: Combination<br> of a Phase 1b open-label trial to evaluate the pharmacokinetics and pharmacodynamics of Tinlarebant<br> in adolescent Japanese STGD1 patients and a Phase 2/3, 24-month, randomized (1:1, active:<br> placebo), double-masked, placebo-controlled, multicenter trial in adolescent STGD1 patients |
|---|---|
| · | The Company enrolled 17<br> subjects in the Phase 2/3 trial, with a target enrollment of approximately 60 subjects, aged<br> 12 to 20 years old, including approximately 10 Japanese subjects. Data from the Japanese<br> subjects are intended to facilitate a future new drug application in Japan. |
| --- | --- |
| · | Primary<br> efficacy endpoint is the growth rate of atrophic lesions; safety and tolerability will also<br> be assessed. |
| --- | --- |
| · | Geographic Atrophy (GA): GA is a chronic degenerative disease of the retina that leads to blindness in the<br> elderly. Accumulation of bisretinoids has been implicated in the progression of GA. There<br> are currently no FDA-approved, orally administered treatments for GA. |
| --- | --- |
| · | PHOENIX Trial: Ongoing,<br> 24-month, randomized (2:1, active: placebo), double-masked, placebo-controlled, global, multi-center,<br> pivotal Phase 3 trial in GA patients |
| --- | --- |
| · | Enrollment completed with 529 subjects. |
| --- | --- |
| · | Primary<br> efficacy endpoint is the growth rate of atrophic lesions; safety and tolerability will also<br> be assessed. |
| --- | --- |
| · | The<br> Company expects to conduct an interim analysis. |
| --- | --- |
Corporate Highlights
| · | On August 8, 2025,<br> the Company completed a registered direct offering of its American Depositary Shares with<br> an existing institutional investor of the Company, raising gross proceeds of approximately<br> $15 million with potential additional proceeds of approximately $15 million if the accompanying<br> warrants were exercised in full. |
|---|
Second Quarter 2025 Financial Results:
Current Assets:
As of June 30, 2025, the Company had $149.2 million in cash, liquidity funds, time deposits, and U.S treasury bills.
R&D Expenses:
For the three months ended June 30, 2025, research and development expenses were $11.0 million compared to $9.1 million for the same period in 2024. For the six months ended June 30, 2025, research and development expenses were $20.4 million compared to $15.8 million for the same period in 2024. The increase in research and development expenses in both the quarter and year-to-date was primarily attributable to (i) higher pass-through expenses related to the PHOENIX trial and manufacturing expenses payments, partially offset by lower DRAGON trial expenses and a development milestone payment for the completion of a phase 2 trial in 2024; (ii) an increase in share-based compensation expenses.
G&A Expenses:
For the three months ended June 30, 2025, general and administrative expenses were $6.5 million compared to $1.4 million for the same period in 2024. For the six months ended June 30, 2025, general and administration expenses were $12.7 million compared to $3.0 million for the same period in 2024. The increase in general and administrative expenses in both the quarter and year-to-date was primarily due to an increase in share-based compensation expenses.
Other Income:
For the three months ended June 30, 2025, other income was $1.3 million compared to $1.0 million for the same period in 2024. For the six months ended June 30, 2025, other income was $2.5 million compared to $1.4 million for the same period in 2024. The increase in both the quarter and year-to-date was attributed to interest from time deposits and U.S. treasury bills.
Net Loss:
For the three months ended June 30, 2025, the Company reported a net loss of $16.3 million, compared to a net loss of $9.5 million for the same period in 2024. For the six months ended June 30, 2025, the Company reported a net loss of $30.6 million, compared to a net loss of $17.4 million for the same period in 2024.
Webcast Information
Belite Bio will host a webcast on Monday, August 11, 2025, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update. To join the webcast, please visit https://events.q4inc.com/attendee/127464226. A replay will be available for approximately 90 days following the event.
About Belite Bio
Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook or visit us at www.belitebio.com.
Important Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements about future expectations and plans, as well as other statements regarding matters that are not historical facts. These statements include but are not limited to statements regarding the potential implications of clinical data for patients, and Belite Bio’s advancement of, and anticipated preclinical activities, clinical development, regulatory milestones, and commercialization of its product candidates, and any other statements containing the words “expect”, “hope” and similar expressions. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Belite Bio’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the timing to complete relevant clinical trials and/or to receive the interim/final data of such clinical trials; the timing to submit trial data to regulatory authorities for drug approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Belite Bio’s drug candidates; the potential efficacy of Tinlarebant, as well as those risks more fully discussed in the “Risk Factors” section in Belite Bio’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Belite Bio, and Belite Bio undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
BELITE BIO, INC
UNAUDITED CONDENSED CONSOLIDATED STATEMENTSOF OPERATIONS AND COMPREHENSIVE LOSS
(Amounts in thousands of US Dollars, exceptshare and per share amounts)
| For the Three<br> Months | For the Six<br> Months | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ended<br> June 30, | Ended<br> June 30, | |||||||||||
| 2024 | 2025 | 2024 | 2025 | |||||||||
| Expenses | ||||||||||||
| Research and development | 9,078 | 11,049 | 15,843 | 20,445 | ||||||||
| General and administrative | 1,393 | 6,547 | 2,956 | 12,668 | ||||||||
| Total operating expenses | 10,471 | 17,596 | 18,799 | 33,113 | ||||||||
| Loss from operations | (10,471 | ) | (17,596 | ) | (18,799 | ) | (33,113 | ) | ||||
| Other income: | ||||||||||||
| Total other income, net | 977 | 1,276 | 1,440 | 2,516 | ||||||||
| Loss before income tax | (9,494 | ) | (16,320 | ) | (17,359 | ) | (30,597 | ) | ||||
| Income tax expense | - | - | 6 | - | ||||||||
| Net loss | (9,494 | ) | (16,320 | ) | (17,365 | ) | (30,597 | ) | ||||
| Other comprehensive income<br> (loss) | ||||||||||||
| Foreign currency translation<br> adjustments, net of nil tax | (10 | ) | 128 | (106 | ) | 146 | ||||||
| Total comprehensive loss | (9,504 | ) | (16,192 | ) | (17,471 | ) | (30,451 | ) | ||||
| Weighted average number of ordinary shares<br> used in per share calculation: | ||||||||||||
| - Basic and Diluted | 30,324,132 | 32,585,043 | 30,000,653 | 32,335,958 | ||||||||
| Net loss per ordinary share | ||||||||||||
| - Basic<br> and Diluted | $ | (0.31 | ) | $ | (0.50 | ) | $ | (0.58 | ) | $ | (0.95 | ) |
BELITE BIO, INC
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands of US Dollars, exceptshare amounts)
| December 31, | June 30, | |||
|---|---|---|---|---|
| 2024 | 2025 | |||
| Current assets | $ | 147,073 | $ | 150,970 |
| Other assets | 5,059 | 5,437 | ||
| TOTAL ASSETS | $ | 152,132 | $ | 156,407 |
| TOTAL LIABILITIES | $ | 6,311 | $ | 6,522 |
| TOTAL SHAREHOLDERS’ EQUITY | 145,821 | 149,885 | ||
| TOTAL LIABILITIES AND SHAREHOLDERS’<br> EQUITY | $ | 152,132 | $ | 156,407 |
| Ordinary shares authorized | 400,000,000 | 400,000,000 | ||
| Ordinary shares issued | 31,857,802 | 32,631,133 | ||
| Ordinary shares outstanding | 31,826,549 | 32,599,298 |
Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com
Julie Fallon
belite@argotpartners.com